Akero Therapeutics (AKRO) Competitors $40.85 +1.24 (+3.13%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. RDY, MRNA, ASND, QGEN, VTRS, ROIV, LNTH, RVMD, BBIO, and TGTXShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Viatris (VTRS), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Dr. Reddy's Laboratories Moderna Ascendis Pharma A/S Qiagen Viatris Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma TG Therapeutics Dr. Reddy's Laboratories (NYSE:RDY) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking. Do institutionals & insiders have more ownership in RDY or AKRO? 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend RDY or AKRO? Dr. Reddy's Laboratories presently has a consensus price target of $17.00, suggesting a potential upside of 24.31%. Akero Therapeutics has a consensus price target of $76.29, suggesting a potential upside of 92.42%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akero Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, RDY or AKRO? Dr. Reddy's Laboratories has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6321.71Akero TherapeuticsN/AN/A-$151.76M-$3.75-10.57 Which has more risk & volatility, RDY or AKRO? Dr. Reddy's Laboratories has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Does the MarketBeat Community believe in RDY or AKRO? Dr. Reddy's Laboratories received 204 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 65.36% of users gave Akero Therapeutics an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Akero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% Is RDY or AKRO more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Akero Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Akero Therapeutics N/A -32.46%-29.83% Does the media refer more to RDY or AKRO? In the previous week, Akero Therapeutics had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Akero Therapeutics and 6 mentions for Dr. Reddy's Laboratories. Akero Therapeutics' average media sentiment score of 1.04 beat Dr. Reddy's Laboratories' score of 0.95 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDr. Reddy's Laboratories beats Akero Therapeutics on 10 of the 17 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$6.51B$5.35B$7.51BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-10.577.0021.9718.05Price / SalesN/A260.09396.62104.31Price / CashN/A65.6738.2034.62Price / Book4.136.346.734.14Net Income-$151.76M$142.49M$3.21B$247.59M7 Day Performance5.36%10.39%5.30%5.65%1 Month Performance-12.05%-7.02%-6.35%-4.54%1 Year Performance95.69%-0.51%16.30%3.14% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics4.1567 of 5 stars$40.85+3.1%$76.29+86.7%+88.8%$3.25BN/A-10.8930Positive NewsGap UpRDYDr. Reddy's Laboratories2.497 of 5 stars$13.25+0.2%$17.00+28.3%-4.4%$11.06B$311.31B21.1024,800MRNAModerna4.4054 of 5 stars$26.80+2.3%$58.70+119.0%-75.4%$10.36B$3.20B-2.893,900Upcoming EarningsASNDAscendis Pharma A/S3.073 of 5 stars$155.50+3.0%$204.64+31.6%+9.2%$9.48B$363.64M-21.901,017Upcoming EarningsNews CoveragePositive NewsQGENQiagen3.5601 of 5 stars$42.30+0.8%$47.71+12.8%+3.9%$9.40B$1.98B117.786,030Analyst ForecastVTRSViatris2.9819 of 5 stars$7.63+1.2%$10.50+37.6%-31.3%$9.11B$14.74B-10.3137,000ROIVRoivant Sciences2.3952 of 5 stars$10.19+3.3%$17.50+71.7%-1.8%$7.27B$122.59M-67.93860Analyst ForecastInsider TradeNews CoveragePositive NewsLNTHLantheus4.4671 of 5 stars$102.13+0.1%$129.43+26.7%+57.1%$6.99B$1.53B16.99700Upcoming EarningsNews CoveragePositive NewsGap UpRVMDRevolution Medicines3.8685 of 5 stars$36.47+2.1%$66.67+82.8%+3.4%$6.78B$742,000.00-10.16250Positive NewsBBIOBridgeBio Pharma4.6276 of 5 stars$34.85+2.8%$52.64+51.0%+38.6%$6.63B$221.90M-12.23400Upcoming EarningsGap UpTGTXTG Therapeutics3.3684 of 5 stars$38.41+4.6%$40.67+5.9%+177.5%$6.03B$329.00M-384.06290Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Moderna Alternatives Ascendis Pharma A/S Alternatives Qiagen Alternatives Viatris Alternatives Roivant Sciences Alternatives Lantheus Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredA Biotech Power Move? This company is leading the charge in developing advanced antiviral therapies—watch closely!With a revolutionary antiviral drug, this company is in a great position to build shareholder value as this ti...Smallcaps Daily | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKRO Stock Free AKRO Stock Alerts